Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 9467

1.

Abstracts from the 2019 Lymphoma and Myeloma Congress October 23-26, 2019 New York, NY.

[No authors listed]

Am J Hematol. 2019 Nov;94 Suppl 2:S3-S33. doi: 10.1002/ajh.25639. No abstract available.

2.

A final listening about ibrutinib in relapsed or refractory CLL: conclusive results from RESONATE sound definitely good!

Merli M, Passamonti F.

Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25662. [Epub ahead of print] No abstract available.

PMID:
31621103
3.

Significant Weight Gain in CLL Patients Treated with Ibrutinib: a Potentially Deleterious Consequence of Therapy.

Williams AM, Baran AM, Schaffer M, Bushart JNP, Rich LNP, Moore J, Barr PM, Zent CS.

Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25663. [Epub ahead of print] No abstract available.

PMID:
31621100
4.

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Herrera AF, Goy A, Mehta A, Ramchandren R, Pagel JM, Svoboda J, Guan S, Hill JS, Kwei K, Liu EA, Phillips T.

Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25659. [Epub ahead of print]

PMID:
31621094
5.

Serotonin-Release Assay-Negative Heparin-Induced Thrombocytopenia.

Warkentin TE, Nazy I, Sheppard JI, Smith JW, Kelton JG, Arnold DM.

Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25660. [Epub ahead of print]

PMID:
31621093
6.

Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: external validation of the IMPEDE VTE score.

Chalayer E, Teste A, Guyotat D, Elalamy I, Leleu X, Tardy B.

Am J Hematol. 2019 Oct 15. doi: 10.1002/ajh.25658. [Epub ahead of print] No abstract available.

PMID:
31617240
7.

Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand Disease.

Abe K, Dupervil B, O'Brien SH, Oakley M, Kulkarni R, Gill JC, Byams V, Soucie MJ; US Hemophilia Treatment Center Network.

Am J Hematol. 2019 Oct 15. doi: 10.1002/ajh.25656. [Epub ahead of print]

PMID:
31612544
8.

Hematopoietic Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Oct 15. doi: 10.1002/ajh.25657. [Epub ahead of print]

PMID:
31612526
9.

Investigation of dabigatran secretion into breast milk: implications for oral thromboprophylaxis in post-partum women.

Ayuk P, Kampouraki E, Truemann A, Sidgwick F, McDonald L, Bingham J, Murphy P, Kamali F.

Am J Hematol. 2019 Oct 10. doi: 10.1002/ajh.25652. [Epub ahead of print] No abstract available.

PMID:
31599003
10.

Methylprednisolone-induced immune thrombocytopenia.

Dubert M, Le Toriellec E, Croisille L, Thomas L, Ducreux M, Froissart A, Herbrecht R, Lebrun-Vignes B, Marolleau JP, Méric JB, Mahevas M, Michel M, Bierling P.

Am J Hematol. 2019 Oct 10. doi: 10.1002/ajh.25645. [Epub ahead of print] No abstract available.

PMID:
31598982
11.

Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.

Srour SA, Saliba RM, Bittencourt MC, Ramos Perez JM, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO.

Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25647. [Epub ahead of print]

PMID:
31595538
12.

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Dalle IA, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F.

Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25648. [Epub ahead of print]

PMID:
31595534
13.

Dissecting the web of ischemic stroke, sickle cell trait, and chronic kidney disease.

Neuberg D.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25649. [Epub ahead of print] No abstract available.

PMID:
31591745
14.

Methodological aspects of the oxygenscan in sickle cell disease: a need for standardization.

Rab MAE, Kanne CK, Bos J, Boisson C, van Oirschot BA, Nader E, Renoux C, Joly P, Fort R, van Beers EJ, Sheehan VA, van Wijk R, Connes P.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25655. [Epub ahead of print] No abstract available.

PMID:
31591742
15.

Hairy cell leukemia 2020: Update on diagnosis, risk-stratification, and treatment.

Maitre E, Cornet E, Troussard X.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25653. [Epub ahead of print]

PMID:
31591741
16.

A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia.

Zhou H, Qin P, Liu Q, Yuan C, Hao Y, Zhang H, Wang Z, Ran X, Chu X, Yu W, Wang X, Hou Y, Peng J, Hou M.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25646. [Epub ahead of print]

PMID:
31591739
17.

Large granular lymphocytic leukemia as a cause of pancytopenia.

Lubowiecki M, Siow W, Eagleton H, Bain BJ.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25650. [Epub ahead of print] No abstract available.

PMID:
31591738
18.

Bone marrow blast elimination by the fifth day of 7+3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
19.

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab as part of their First Induction Regimen for Multiple Myeloma.

Al Saleh AS, Sidiqi MH, Gertz MA, Muchtar E, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Buadi FK, Dispenzieri A, Dingli D, Kumar SK.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25654. [Epub ahead of print] No abstract available.

PMID:
31591735
20.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25644. [Epub ahead of print] No abstract available.

PMID:
31588594

Supplemental Content

Loading ...
Support Center